Catherine Pickering, iOnctura CEO
iOnctura raises €80M to advance early-stage rare eye cancer treatment
iOnctura has collected €80 million ($85.9 million) in a Series B round to support its lead cancer candidate through a Phase 2 test in uveal …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
